


**Name:** Shafi Ullah Khan

**E-mail:** [shafi-ullah.khan@unicaen.fr](mailto:shafi-ullah.khan@unicaen.fr) ;  
[shafiullahpharmd@gmail.com](mailto:shafiullahpharmd@gmail.com)

**ORCID:** <http://orcid.org/0000-0001-9231-1831>



**Short Bio:**

**2008-2014:** Pharmaceutical Sciences (Pharm-D) at Gomal University, D.I. Khan, Pakistan.

**2014-2016:** Pharmaceutical Chemistry (M.S.) at COMSATS University, Abbottabad, Pakistan.

**2017-2021:** Ph.D. in Medicinal Chemistry from Monash University, Australia.

**2023- present:** Marie Skłodowska-Curie Postdoctoral Fellow at INSERM U1086 ANTICIPE, University of Caen Normandy, France

**Research interests:** Medicinal chemistry, including **drug design**, synthesis, biological evaluation, and computational studies. Expertise spans the entire drug discovery pipeline. Specific research focus includes developing **UBE2N inhibitors** for the sensitization of ovarian cancers to PARP inhibitors, and research involving small molecules targeting **G protein-coupled Estrogen Receptor 1 (GPER1)** in resistant breast cancer.

Key methodologies include **Computer-Aided Drug Design (CADD)**, encompassing virtual screening, molecular docking, and **molecular dynamics (MD) simulations**. Research utilizes synthetic chemistry and compound characterization (e.g., TLC, FTIR, NMR, HPLC, LC-MS), and biological evaluation using cell-based assays, ligand binding assays, and enzymatic inhibition studies, including establishing Microscale Thermophoresis (MST) methodology.

A testament to his research excellence, Dr. Khan is a recipient of the prestigious **Marie Skłodowska-Curie Postdoctoral Award in 2023**. He was also the winner of the **BioSolveIT Scientific Challenge Fall 2024**. His significant research productivity is highlighted by his extensive publication record, with **69 peer-reviewed papers**.